VivoSeq
Other

Biomarker

0

Pipeline Programs↗

14

Active Trials↗

11

Companies Involved↗

Biomarker is an early-stage landscape with 0 programs across 11 companies. The most active players are Seaside Therapeutics, Inc., ProQR Therapeutics, Fulcrum Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

32/100

Mech. Concentration

N/A

Completion Rate

78/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Seaside Therapeutics, Inc.

0 programs

PreclinicalP

ProQR Therapeutics

0 programs

PreclinicalF

Fulcrum Therapeutics

0 programs

PreclinicalA

Alterity Therapeutics

0 programs

PreclinicalC

Cancer Prevention Pharmaceuticals, Inc.

0 programs

PreclinicalGSK logo

GSK

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

59

clinical trials

Completed29 · 49%
Unknown status8 · 14%
Not yet recruiting8 · 14%
Terminated6 · 10%
Recruiting4 · 7%
Withdrawn2 · 3%
Other2 · 3%

Clinical Trials

Trial Activity

59 trials

New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome
Recruiting·AAssistance Publique - Hôpitaux de Paris·N/A·NCT06694363·14 enrolled
Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis
Recruiting·UUniversity of Wisconsin, Madison·Phase 2·NCT06940427·50 enrolled
Use of CXCL9 as a Biomarker of Acthar Efficacy
Recruiting·UUniversity of California, San Francisco·Phase 4·NCT02523092·14 enrolled
Dissolved Phase HXe-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology
Recruiting·—·Phase 2/3·NCT06856525·80 enrolled
This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling
Not yet recruiting·GGipfel Life Sciences GmbH·Phase 2/3·NCT07321860·60 enrolled
Ketamine Biomarker Validation
Not yet recruiting·SSoterix Medical·Phase 1·NCT07307768·20 enrolled
Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial
Not yet recruiting·UUniversità Vita-Salute San Raffaele·Phase 2·NCT07274384·74 enrolled
Biomarker and Renal Angina Validation to Assess Heart-Kidney Outcomes After Amino Acid Therapy
Not yet recruiting·—·Phase 2·NCT07212595·30 enrolled
Umbrella Biomarker-Guided Therapy in NPC
Not yet recruiting·SSun Yat-sen University·Phase 2·NCT04605562·206 enrolled
A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.
Not yet recruiting·QQueen's University·Phase 1/2·NCT07064863·31 enrolled
Study of [11C]CPPC as a Clinical PET Radioligand Biomarker of Microglial Activation in ALS
Not yet recruiting·JJohns Hopkins University·Phase 1/2·NCT05602142·20 enrolled
Biomarker-based Trial of NPC-1 for Alzheimer's Pathology
Not yet recruiting·MMassachusetts General Hospital·Phase 1/2·NCT07236190·40 enrolled
Pain Biomarker Study
Enrolling by invitation·TThe University of Texas Health Science Center, Houston·Phase 1·NCT03511846·371 enrolled
Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA
Enrolling by invitation·—·Phase 4·NCT07343661·90 enrolled
A Biomarker-directed Study of XPro1595 in Patients With Alzheimer's
Completed·IInmune Bio, Inc.·Phase 1·NCT03943264·20 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)